Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherRevenue (Gross)Shares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Design Therapeutics (DSGN) Receivables - Other (2020 - 2026)

Design Therapeutics' Receivables - Other history spans 2 years, with the latest figure at $110000.0 for Q4 2021.

  • On a quarterly basis, Receivables - Other rose 1000.0% to $110000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $110000.0, a 1000.0% increase, with the full-year FY2021 number at $110000.0, up 1000.0% from a year prior.
  • Receivables - Other hit $110000.0 in Q4 2021 for Design Therapeutics, up from $47000.0 in the prior quarter.
  • Over the last five years, Receivables - Other for DSGN hit a ceiling of $110000.0 in Q4 2021 and a floor of $10000.0 in Q4 2020.